Literature DB >> 17498654

SUMO modification modulates the transrepression activity of PLZF.

Ting-Ting Chao1, Che-Chang Chang, Hsiu-Ming Shih.   

Abstract

Small ubiquitin-like modifier (SUMO) modification has recently been shown to associate with transcriptional regulation and nuclear body formation. Here, we show that transcription factor PLZF can be SUMO modified at lysine residue 242, 387 and 396. Converting these three SUMO acceptor Lys to Arg 3KR does not significantly affect PLZF nuclear body formation, which is distinct from the scenario of PML sumoylation in PML nuclear body formation. Furthermore, PLZF-3KR markedly reduced the transcriptional repression activity, correlating with a loss of PLZF-mediated growth suppression. These results reveal an important role of SUMO modification in PLZF-mediated transcriptional repression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498654     DOI: 10.1016/j.bbrc.2007.04.157

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology.

Authors:  Byoung Kwon Yoo; Luni Emdad; Seok-Geun Lee; Zao-zhong Su; Prasanna Santhekadur; Dong Chen; Rachel Gredler; Paul B Fisher; Devanand Sarkar
Journal:  Pharmacol Ther       Date:  2011-01-20       Impact factor: 12.310

2.  Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα.

Authors:  Qian-Qian Wang; Liaqat Hussain; Pei-Han Yu; Chang Yang; Chen-Ying Zhu; Ya-Fang Ma; Si-Chun Wang; Tao Yang; Yuan-Yuan Kang; Wen-Juan Yu; Yasen Maimaitiyiming; Hua Naranmandura
Journal:  Acta Pharmacol Sin       Date:  2022-10-10       Impact factor: 7.169

3.  HIC1 interacts with and modulates the activity of STAT3.

Authors:  Ying-Mei Lin; Chia-Mei Wang; Jen-Chong Jeng; Dominique Leprince; Hsiu-Ming Shih
Journal:  Cell Cycle       Date:  2013-07-15       Impact factor: 4.534

4.  Nucleus accumbens associated 1 is recruited within the promyelocytic leukemia nuclear body through SUMO modification.

Authors:  Yoshinori Tatemichi; Masahiko Shibazaki; Shinji Yasuhira; Shuya Kasai; Hiroshi Tada; Hiroki Oikawa; Yuji Suzuki; Yasuhiro Takikawa; Tomoyuki Masuda; Chihaya Maesawa
Journal:  Cancer Sci       Date:  2015-05-26       Impact factor: 6.716

5.  Analysis of the interaction between Zinc finger protein 179 (Znf179) and promyelocytic leukemia zinc finger (Plzf).

Authors:  Ding-Yen Lin; Chi-Chen Huang; Ya-Ting Hsieh; Hsin-Chuan Lin; Ping-Chieh Pao; Jen-Hui Tsou; Chien-Ying Lai; Liang-Yi Hung; Ju-Ming Wang; Wen-Chang Chang; Yi-Chao Lee
Journal:  J Biomed Sci       Date:  2013-12-20       Impact factor: 8.410

6.  HIC1 (hypermethylated in cancer 1) SUMOylation is dispensable for DNA repair but is essential for the apoptotic DNA damage response (DDR) to irreparable DNA double-strand breaks (DSBs).

Authors:  Sonia Paget; Marion Dubuissez; Vanessa Dehennaut; Joe Nassour; Brennan T Harmon; Nathalie Spruyt; Ingrid Loison; Corinne Abbadie; Brian R Rood; Dominique Leprince
Journal:  Oncotarget       Date:  2017-01-10

7.  Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity.

Authors:  Myriam Koubi; Mathilde Poplineau; Julien Vernerey; Lia N'Guyen; Guillaume Tiberi; Sylvain Garciaz; Abdessamad El-Kaoutari; Muhammad A Maqbool; Jean-Christophe Andrau; Christel Guillouf; Andrew J Saurin; Estelle Duprez
Journal:  Nucleic Acids Res       Date:  2018-04-20       Impact factor: 16.971

Review 8.  A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics.

Authors:  Ellen Van Damme; Kris Laukens; Thanh Hai Dang; Xaveer Van Ostade
Journal:  Int J Biol Sci       Date:  2010-01-12       Impact factor: 6.580

9.  Interleukin-32α downregulates the activity of the B-cell CLL/lymphoma 6 protein by inhibiting protein kinase Cε-dependent SUMO-2 modification.

Authors:  Yun Sun Park; Jeong-Woo Kang; Dong Hun Lee; Man Sub Kim; Yesol Bak; Young Yang; Hee Gu Lee; JinTae Hong; Do-Young Yoon
Journal:  Oncotarget       Date:  2014-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.